Regulatory Overview
Peptide Legal & Regulatory Status
The regulatory landscape for peptides varies significantly by jurisdiction. This page summarizes FDA status, WADA classification, and common administration routes across all profiled peptides.
- Routes
- Injectable, Oral
- Notes
- FDA GRAS status as food ingredient
- Routes
- Injectable
- Notes
- Currently FDA Category 2 (not compoundable). Formal reclassification to Category 1 announced Feb 27, 2026 but not yet published as of April 14, 2026.
- Routes
- Injectable
- Notes
- Vyleesi — approved June 2019 for HSDD in premenopausal women
- Routes
- Injectable, Oral
- Notes
- FDA-approved December 2017 (Ozempic) for type 2 diabetes; FDA-approved June 2021 (Wegovy, 2.4 mg) for chronic weight management; FDA-approved September 2019 (Rybelsus, oral) for type 2 diabetes.
- Routes
- Injectable
- Notes
- FDA-approved 1997 (Geref) for diagnosis and treatment of pediatric growth hormone deficiency. The original Geref product was discontinued by Serono in 2008; sermorelin acetate is currently available through 503A compounding pharmacies in the US as a compounded prescription.
- Routes
- Injectable
- Notes
- Forzinity — approved Sept 2025 for Barth syndrome
- Routes
- Injectable
- Notes
- FDA-approved November 2010 (Egrifta) for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. FDA-approved May 2019 (Egrifta SV, a reformulated version) for the same indication.
- Routes
- Injectable
- Notes
- Zadaxin — approved in ~35 countries for hepatitis B/C
- Routes
- Injectable
- Notes
- FDA-approved May 2022 (Mounjaro) for type 2 diabetes; FDA-approved November 2023 (Zepbound) for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity.
Understanding Regulatory Categories
FDA-Approved
Peptides with at least one FDA-approved indication have undergone rigorous clinical trials demonstrating safety and efficacy for a specific use. FDA approval does not mean the peptide is approved for all potential applications discussed in research literature.
Approved Abroad
Some peptides have received marketing authorization from regulatory bodies outside the United States, such as the European Medicines Agency (EMA) or national health agencies in Russia, Japan, or Australia. These approvals may not transfer across jurisdictions.
Investigational
Investigational peptides are currently or have been studied in human clinical trials but have not yet received regulatory approval. They may be available through clinical trial enrollment or compassionate use programs in some jurisdictions.
Research Only
Research-only peptides are sold exclusively for in vitro or animal research. They have not been approved by any regulatory body for human use. Purchasing or possessing these compounds may be subject to local laws and regulations.
Important Disclaimers
Regulatory classifications can change as new clinical data emerges and government agencies update their guidelines. The information on this page reflects our best understanding as of the date shown below and should not be relied upon as legal advice.
- Always verify the current legal status of any peptide in your specific jurisdiction before purchasing, possessing, or using it.
- Consult with qualified legal counsel if you have questions about the legality of specific peptides in your country or state.
- This page does not constitute medical advice. Consult a licensed healthcare professional before using any peptide for therapeutic purposes.
- WADA prohibitions apply to athletes subject to anti-doping testing. If you are a competitive athlete, consult your sport governing body for the most current prohibited list.
Last updated: March 2026